[A20-116] Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V
Last updated 04.06.2021
Project no.:
A20-116
Commission:
Commission awarded on 14.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation.
PD-L1 expression (TPS) of at least 50 percent: added benefit not proven.
PD-L1 expression (TPS) below 50 percent: non-squamous histology: indication of added benefit; extent “non-quantifiable". Squamous histology: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-12 | Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-44 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-12 | Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A13-44 | Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-07 | Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A21-56 | Ipilimumab (NSCLC) - Addendum to Commission A20-116 | Commission completed |
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.